Vol 5, Issue 5
Pages 794–802
Published: 11 Oct 2021
Michal Mandelboim1, 2, Ella Mendelson1, 2, Yaron Drori1, 2, Nofar Atari1, Tair Lapidot3*, Dalia Megiddo3*, Micha Gladnikoff4
Article Information
Citation: Michal Mandelboim, Ella Mendelson, Yaron Drori, Nofar Atari, Tair Lapidot, Dalia Megiddo, Micha Gladnikoff. Taffix® Nasal Powder Spray Forms an Effective Barrier Against Infectious New Variants of SARS-Cov-2 (Alpha, Beta and Delta). Archives of Clinical and Biomedical Research 5 (2021): 794-802.
DOI: 10.26502/acbr.50170202
Share
Abstract
While vaccination efforts against SARS-CoV-2 around the world are ongoing, new highly infectious virus variants continue to evolve. The protection provided by the available vaccines against some of the new variants is weaker. Additional preventive measures will therefore be needed to protect the population until effective vaccinations are widely available. TaffiX® is an anti-viral nasal powder spray comprised of low-pH hypromellose, which forms a protective mechanical barrier that prevents viruses from engaging with nasal cells. The current study aimed to test the protective effect of TaffiX® against SARS-CoV-2 Alpha (B.1.1.7; hCoV-19/Israel/CVL-46879-ngs/ 2020), Beta, (B.1.351; hCoV-19/Israel/CVL-2557-ngs/2020) and Delta (B.1.617.2; hCoV-19/Israel/ VVL-12806/2021), three highly infectious and pathogenic SARS-CoV-2 strains.
Keywords
CoVID-19; SARS-CoV-2; Variant B.1.1.7; Variant B.1.351; Variant B.1.617.2; Variant Alpha; Variant Beta; Variant Delta; Taffix; Nasal Spray
CoVID-19 articles; SARS-CoV-2 articles; Variant B.1.1.7 articles; Variant B.1.351 articles; Variant B.1.617.2 articles; Variant Alpha articles; Variant Beta articles; Variant Delta articles; Taffix; Nasal Spray articles
Article Details
1. Introduction